CollPlant announces publication highlighting its rhCollagen-based photocurable skin filler in the Journal of Plastic and Reconstructive Surgery

Preclinical modeling demonstrates the potential of filler to enhance cell proliferation and regeneration of new tissues for aesthetic medicine applications

REHOVOT, Israel, December 2, 2021 / PRNewswire / – CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ fabrication, today announced the publication of an article in the journal Plastic and Reconstructive Surgery entitled “The potential use of the new recombinant human collagen of plant origin in aesthetic medicine. ”The article highlights in vitro and in vivo results of CollPlant’s photocurable dermal filler as well as other potential applications of this collagen technology in aesthetic medicine.

After light skin lightening, CollPlant’s photocurable dermal filler showed improved physical properties compared to standard skincare, suggesting an improved lifting effect and appearance. Biological properties evaluated in a preclinical animal model showed that the photocurable filler improves cell proliferation and new tissue regeneration compared to standard care.

“We are very pleased with these promising results from CollPlant’s photocurable collagen technology, demonstrating its broad potential in aesthetic medicine applications,” said Yehiel Tal, CEO of CollPlant. “Regenerative medicine aims to mimic nature, providing cells with a growth environment as similar as possible to the original one. These published results further demonstrate the ability of recombinant human collagen (rhCollagen) to serve as an ideal building block in regenerative medicine applications, ”added Yehiel.

CollPlant’s photocurable dermal filler is composed of rhCollagen and hyaluronic acid and is intended for the correction of contour imperfections. The filler is designed to allow easy injection, followed by in situ shaping and hardening by light skin lighting.

the Plastic and Reconstructive Surgery Journal is the official medical journal of the American Society of Plastic Surgeons, the world’s largest organization of board-certified plastic surgeons, representing more than 7,000 member surgeons.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company specializing in 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its recombinant human collagen produced with CollPlant’s proprietary plant-based genetic engineering technology. These products meet indications for the various fields of tissue repair, aesthetics and organ fabrication, and usher in a new era in regenerative and aesthetic medicine.

In early 2021, CollPlant entered into a global development and marketing agreement for dermal fillers and soft tissue products with Allergan, an AbbVie company, a world leader in the dermal fillers market. Later in 2021, CollPlant entered into a strategic co-development agreement with 3D Systems for a 3D bio-printed regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information visit http://www.collplant.com.

Safe Harbor declarations

This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives, plans and strategies, as well as statements, other than historical facts, which relate to activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or could occur in the future. These statements are often characterized by words such as “believes”, “hopes”, “could”, “anticipates”, “should”, “intends”, “plans”, “will”, “expects”. “,” Estimates “,” “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties which could cause actual results to differ materially from those expressed or implied in such statements. There are many factors that could cause CollPlant’s activities or actual results to differ materially from the activities and results anticipated in the forward-looking statements, including, but not limited to, the following: company, its ability to continue to operate, and its need to raise additional capital and its inability to raise additional capital on acceptable terms, if at all; the impact of the COVID-19 pandemic; the Company’s expectations regarding the timing and cost of commencing clinical trials for tissues and organs that are based on its rhCollagen-based BioInk and its medical aesthetic products; the Company’s ability to obtain favorable preclinical and clinical trial results; regulatory action regarding rhCollagen based bio-ink and medical aesthetic products, including, but not limited to, accepting a Marketing Authorization Review application and approval of this request, and, if approved, the scope of the approved indication and labeling; the commercial success and market acceptance of the Company’s rhCollagen-based products in 3D bioprinting and medical aesthetics; the Company’s ability to build sales and marketing capabilities or to enter into agreements with third parties and its dependence on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s dependence on third parties to carry out some or all aspects of the manufacture of its products; the extent of the protection that the Company is able to establish and maintain for intellectual property rights and the ability of the Company to conduct its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information on the risks and uncertainties affecting CollPlant is contained in the section “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other documents. that CollPlant has filed and may file with the SEC. in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise forward-looking statements. whether as a result of new information, future events or otherwise.

Contact at CollPlant:

Eran Rotem
Deputy CEO and CFO
Phone: + 972-73-2325600 / 631
E-mail: [email protected]

SOURCE CollPlant